BIOGNOSYS
19.5.2022 14:02:08 CEST | Business Wire | Press release
Biognosys, a leader in next-generation proteomics solutions for life science research and drug development, announced today the appointment of Beat Lüthi, Ph.D., as Board Director.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220519005079/en/
Dr. Lüthi is Chief Executive Officer of CTC Analytics AG, a privately owned Swiss company leading in automation and advanced laboratory sample handling solutions for the pharmaceutical, life science, chemical, environmental, and food & flavor industries. Additionally, he holds several Board of Directors mandates in public firms, including Chairman of Inficon Group, Vice Chairman of Straumann Group, and Board Member of Skan AG.
Dr. Lüthi holds an M.Sc. in Electrical Engineering and a Ph.D. in Business Administration from ETH Zurich and completed an International Executive Program at the INSEAD Business School.
As Board Director at Biognosys, Dr. Lüthi will be instrumental in the company’s transformation to a leading provider and partner for protein insights to drive the development of new breakthrough treatments.
“I am excited to join Biognosys at a time when proteomics is widely adopted to accelerate life science research and development,” said Dr. Lüthi, incoming Board Director at Biognosys. “The company is at an inflection point of strengthening its global leadership position in the proteomics field and I am looking forward to being part of this journey.”
“I am delighted to welcome Dr. Lüthi as Board Director to support our next growth stage with his extensive experience as life sciences executive and board director,” commented Dr. Oliver Rinner, CEO of Biognosys. I would also like to thank our prior Board Director, Winfried Mayer, for his many years of invaluable service to our board.”
About Biognosys
At Biognosys, we believe that deep proteome insights hold the key to breakthrough discoveries that can dramatically improve human health. We enable life science researchers and drug hunters to look at the proteome from every angle with our versatile portfolio of proprietary next-generation proteomics services, software, and kits, including the TrueDiscovery™, TrueTarget™, and TrueSignature™ platforms and flagship software Spectronaut™. These solutions provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. For more information, visit biognosys.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220519005079/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
1NCE and Pessl Instruments Connect Smart Farms Worldwide29.7.2026 10:00:00 CEST | Press release
IoT specialists 1NCE and Pessl Instruments help farmers in 80 countries to connect and manage thousands of weather stations Smart farming solution improves water and fertilizer efficiency Both companies provide critical components at a 99.97% service availability 1NCE, a company offering a plug-and-play platform for creating and managing the world’s best IoT products, and Pessl Instruments, a global leader in smart agriculture, announce today the roll-out of the METOS by Pessl Instruments weather network solution powered by 1NCE. The smart farming solution provided by Pessl Instruments connects thousands of weather stations and field sensors through a single platform, providing farmers real-time data of precipitation and soil moisture, extreme weather forecasting and crop disease risk in more than 80 countries. The main challenge for the deployment of smart farming solutions is always providing good coverage in rural areas. Thanks to 1NCE’s global connectivity service available in more
Cognita Reply Named an OpenAI Advanced Partner to Accelerate Enterprise Adoption of Frontier AI29.7.2026 10:00:00 CEST | Press release
Cognita Reply, the Reply Group company specialising in OpenAI technologies, today announced that it has been named an OpenAI Advanced Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729234340/en/ Cognita Reply, the Reply Group company specialising in OpenAI technologies, today announced that it has been named an OpenAI Advanced Partner within the OpenAI Partner Network, to accelerate enterprise adoption of frontier AI The OpenAI Partner Network is a global programme for partners to build, sell and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities and customer relationships, while equipping them with resources, enablement and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. We’re pleased to welcome Cognita Reply as an OpenAI Advanced Partner. The Cognita Reply
T964 Named as Uptime Institute Business Partner to Power Iraq’s Digital Infrastructure29.7.2026 09:02:00 CEST | Press release
Agreement signed at U.S.-Iraq Business Summit brings the world’s most trusted digital infrastructure standards to Iraq Uptime Institute and Tech964 Holding Limited (T964), Iraq’s leading digital infrastructure company, today announced a landmark strategic partnership to accelerate Iraq’s digital transformation. The partnership combines the world’s leading authority in digital infrastructure standards with the company building the critical infrastructure underpinning Iraq’s digital economy. The agreement was signed at the U.S. Chamber of Commerce U.S.-Iraq Business Summit on July 17, 2026, during the official U.S. visit of Iraqi Prime Minister Ali Al-Zaidi, at a historic summit that produced more than 50 agreements valued at over USD $60 billion and marked a powerful new era of economic cooperation between the United States and Iraq. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260728066813/en/ T964 named as Uptime Institut
ELFA Vape Aerosols Less Harmful Than Cigarette Smoke: Study29.7.2026 09:00:00 CEST | Press release
Levels of 17 analytes usually found in cigarette smoke tested in aerosols from ELFBAR ELFA pods 10 harmful constituents below detectable levels, with formaldehyde and acetaldehyde up to 99.9%* lower than those in cigarette smoke Metals detected well below safety thresholds Complete switching to ELFA significantly reduces or brings to zero adult users’ exposure to harmful constituents Levels of 17 constituents in aerosols from ELFA, a pod system vape by ELFBAR, are undetected or substantially lower than those in cigarette smoke, reveals the latest peer-reviewed study published by iScience, a scientific journal. Aerosols in this study are generated by facilities under standardized laboratory conditions. The tests involve 17 cigarette smoke-related analytes during vaporization of vape liquid from ELFA’s pods in four flavors, including Super Tobacco, Spearmint, Strawberry Ice and Watermelon. Findings indicate that adult smokers completely transitioning to ELFA pod system could reduce, or e
PK MED Strengthens Its Strategic and Scientific Governance to Support the Development of Its Therapeutic Micro-implants29.7.2026 09:00:00 CEST | Press release
François Romaneix is appointed Chairman of the Board of Directors.Prof. Philippe Leboulch joins the Board of Directors and the Scientific Advisory Board.Prof. Alain Fischer becomes Chairman of the Scientific Advisory Board.Isabelle Buckle and Tom Tice are appointed to the Board of Directors. PK MED, a French biotechnology company founded by Truffle Capital (founder of Abivax and Carvolix), developing therapeutic micro-implants to address major medical needs, today announces a significant strengthening of its governance. The company is strengthening the structure of its Board of Directors and Scientific Advisory Board to support the upcoming Phase 2 entry of its most advanced drug candidate, ARTHRELIS (treatment of gout flares), and to accelerate the preclinical development of ENGRAFTIS (treatment of poor graft function following bone marrow transplantation). The Board of Directors of PK MED welcomes four key new members: François Romaneix, appointed Chairman of the Board of Directors.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom